Management of treatment-associated toxicites of anti-angiogenic therapy in patients with brain tumors.
about
Practical management of bevacizumab-related toxicities in glioblastomaPhase 2 study of CT-322, a targeted biologic inhibitor of VEGFR-2 based on a domain of human fibronectin, in recurrent glioblastoma.Antiangiogenic therapy of brain tumors: the role of bevacizumab.Migration capacity of human umbilical cord mesenchymal stem cells towards glioma in vivoEndothelial cell FGF signaling is required for injury response but not for vascular homeostasis.The impact of bevacizumab treatment on survival and quality of life in newly diagnosed glioblastoma patients.Primary brain tumors and posterior reversible encephalopathy syndromeHOXB1 Is a Tumor Suppressor Gene Regulated by miR-3175 in Glioma.Efficacy and safety of bevacizumab for the treatment of glioblastoma.Cerebral Blood Flow Changes in Glioblastoma Patients Undergoing Bevacizumab Treatment Are Seen in Both Tumor and Normal Brain.Overexpression of RACK1 Promotes Metastasis by Enhancing Epithelial-Mesenchymal Transition and Predicts Poor Prognosis in Human Glioma.Update on bevacizumab and other angiogenesis inhibitors for brain cancer.Safety of bevacizumab in patients with malignant gliomas: a systematic review.Bevacizumab for the treatment of high-grade glioma: an update after phase III trials.Targeting vascular and leukocyte communication in angiogenesis, inflammation and fibrosis.NRG oncology RTOG 0625: a randomized phase II trial of bevacizumab with either irinotecan or dose-dense temozolomide in recurrent glioblastoma.Wound healing complications in brain tumor patients on Bevacizumab.Anti-angiogenic therapy in high-grade glioma (treatment and toxicity).Bevacizumab and gefitinib enhanced whole-brain radiation therapy for brain metastases due to non-small-cell lung cancer.MiR-136 targets E2F1 to reverse cisplatin chemosensitivity in glioma cells.Atypical reversible posterior leukoencephalopathy syndrome (RPLS) induced by cediranib in a patient with metastatic rectal cancer.Flubendazole inhibits glioma proliferation by G2/M cell cycle arrest and pro-apoptosis.
P2860
Q27015852-78CC78E8-8644-4689-9C36-7E15DAE4ED8DQ30301304-6B758B70-411C-4E29-9720-4C563121F0F7Q30737224-039F92F4-B60C-4796-B8A7-085D6B74FEB6Q34095283-35337580-5EDF-4D34-B5B4-6463B9148FCEQ34218313-23D614F9-A1F7-4181-AFA9-5E2F9548AB19Q34293163-81A4E1B8-D946-499E-91C3-879EE995CE22Q35206252-7AEBC38B-7D7C-4D86-9A30-63D0C8EC9681Q35840631-C607DAAD-8AFE-40AD-B6D8-68BD6935DE4EQ36523864-0F3ED767-F0DA-4369-B6F5-601DC61FAE68Q36589758-1A5A0257-F924-4C3F-93CB-A7ED36E4C188Q37379251-D4281F6F-FE1C-4ABF-81E1-95F33C96DF3AQ38106370-1BE0B43F-0355-438E-8EBF-E36046AC50A7Q38166676-A39D8D05-2B8B-49BB-84A9-43329A0AEC29Q38198121-6970064B-9BB2-48DB-87C1-C1F292E3355AQ38650120-92DA35F6-3813-431E-9FC1-F1A8D318F800Q39259854-5EAC2FF5-389A-46DF-88EB-4CCE28945976Q40616500-8F282C5F-BA85-4C53-A29B-8C5821B87325Q40705444-AB9432C2-167D-44D9-91A7-7CEB6C43B3B5Q47142558-E286025E-D856-4C35-B075-9ADFE137471DQ48595565-F0BF4AF3-65C4-4B65-8404-583773492167Q48774492-395D356A-8510-4321-A694-F28AA07016C5Q52659227-A20437BF-AB4C-4B5E-97CA-6356E2A2004D
P2860
Management of treatment-associated toxicites of anti-angiogenic therapy in patients with brain tumors.
description
2012 nî lūn-bûn
@nan
2012 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
name
Management of treatment-associ ...... in patients with brain tumors.
@ast
Management of treatment-associ ...... in patients with brain tumors.
@en
type
label
Management of treatment-associ ...... in patients with brain tumors.
@ast
Management of treatment-associ ...... in patients with brain tumors.
@en
prefLabel
Management of treatment-associ ...... in patients with brain tumors.
@ast
Management of treatment-associ ...... in patients with brain tumors.
@en
P2093
P2860
P356
P1433
P1476
Management of treatment-associ ...... in patients with brain tumors
@en
P2093
David Schiff
Mark R Gilbert
Patrick Y Wen
P2860
P304
P356
10.1093/NEUONC/NOR223
P577
2012-02-03T00:00:00Z